Key result
Empagliflozin fails to improve peak exercise PCWP to cardiac index ratio versus placebo in HFrEF.
Why the study?
SGLT2 inhibitors improve outcomes in HFrEF, but the mechanism by which they improve outcomes remains unclear.
Does empagliflozin 10 mg once daily improve the ratio of pulmonary capillary wedge pressure to cardiac index at peak exercise in patients with HFrEF?
RCT (n=70)
Double-blind
randomized
Does empagliflozin 10 mg once daily improve the ratio of pulmonary capillary wedge pressure to cardiac index at peak exercise in patients with HFrEF?
Mean Difference: -0.13 (95% CI -1.6–1.34)
p-value: p=0.86
In patients with HFrEF, 12 weeks of empagliflozin did not improve the primary hemodynamic endpoint of peak PCWP/CI, but did significantly reduce PCWP across all exercise loads.
No takes yet. Share an insight, caveat, or question.
Empagliflozin unloads the heart in HFrEF; extends outcome trials with direct hemodynamic confirmation in this RCT.
Omar et al. (2020) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) (n=70). Empagliflozin vs. Placebo was evaluated on Ratio of pulmonary capillary wedge pressure (PCWP) to cardiac index (CI) at peak exercise after 12 weeks (MD -0.13, 95% CI -1.60 to 1.34, p=0.86). Empagliflozin for 12 weeks did not significantly improve the ratio of PCWP to CI at peak exercise compared with placebo in patients with HFrEF (MD -0.13; 95% CI -1.60 to 1.34; p=0.86).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: